search
Back to results

Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia (CORTEX-SP)

Primary Purpose

Schizophrenia

Status
Unknown status
Phase
Not Applicable
Locations
Spain
Study Type
Interventional
Intervention
Aerobic Exercise
Cognitive Training
Treatment as usual
Occupational Activities
Sponsored by
Red Salud Mental Araba
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Schizophrenia focused on measuring Cognitive remediation, Aerobic exercise, Physical exercise, Negative symptoms, Functional outcome, Cognition

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Diagnosis of Schizophrenia (DSM-5 F20.9)
  • More than 2 years since the onset of the disease.
  • Stable cognitive impairment.
  • Moderate severity of cognitive impairment in MATRICS scores (T score < 40 in, at least, 1 out of 7 cognitive domains).

Exclusion Criteria:

  • Subjects clinically unstable (PANSS positive score > 19).
  • Cognitive impairment due to another medical condition (neurocognitive disorders, brain injury, intellectual disability, etc.)

Sites / Locations

  • Hospital Psiquiatrico de Alava. Red Salud Mental de ArabaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Sham Comparator

Arm Label

Aerobic Exercise

Cognitive Training

Treatment as usual

Arm Description

This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).

The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.

The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.

Outcomes

Primary Outcome Measures

Grey Matter Volume Change
Assessment of Grey Matter volume changes (T1-weighted MRI) among the 3 groups using Voxel Based Morphometry (VBM).
Fractional Anisotropy Change
Assessment of changes in fractional anisotropy of White Matter fibers by Diffusion Tensor MR Imaging and using the Tract-Based Spatial Statistics (TBSS).
Functional Magnetic Resonance Imaging (fMRI) Change at Rest
Assessment of changes in fMRI at rest with the Coon Functional Connectivity Toolbox.
Functional Magnetic Resonance Imaging (fMRI) Change during the performance of a cognitive paradigm.
Assessment of changes in fMRI during the performance of a cognitive paradigm with Statistical Parametric Mapping (SPM8).

Secondary Outcome Measures

Serum BDNF
Assessment of changes in serum BDNF using ELISA immuno-assay techniques. Measured in ng/ml.
Clinical Symptoms of Schizophrenia measured by the Positive and Negative Symptoms Scale (PANSS).
Severity of the negative symptoms will be assessed with the total score of the Subscale for Negative Symptoms of the PANSS scale, which comprises 7 items, each one measuring a specific negative symptom. Each item ranges from 1 (absence of the symptom) to 7 (extreme severity of the symptom). Total score of the Negative Subscale of the PANSS ranges from 7 (minimum score) to 49 (maximum severity). Severity of positive symptoms will be assessed with the total score of the Subscale for Positive Symptoms of the PANSS, which comprises 7 items ranging from 1 (absence of the symptom) to 7 (extreme severity of the symptom). Total score of the Positive Subscale ranges from 7 (minimun score) to 49 (maximun severity). General Psychopathology will be assessed with the total score of the General Psychopathology Subscale which comprises 16 items ranging from 1(absence of the symptom) to 7 (extreme severity of the symptom).
Negative Symptoms of Schizophrenia measured by the Brief Negative Symptoms Scale (BNSS).
Severity of negative symptoms will be assessed with the total score of the BNSS. Values ranges from 0 (total absence of negative symptoms) to 90 (maximum severity of negative symptoms).
Negative Symptoms of Schizophrenia measured by the Clinical Assessment Interview for Negative Symptoms Scale (CAINS)
Severity of negative symptoms will be assessed with the total score of the CAINS scale. Values ranges from 0 (total absence of negative symptoms) to 52 (maximum severity of negative symptoms).
Functional Outcome measured by the UCSD Performance Based Assessment of Functional Skills in Severe Mental Illness (UPSA).
The UPSA includes the following 5 subscales: Financial Skills, Communication, Comprehension/Planning, Transportation, Household Management. Total scores for each subscale are calculated by transforming raw scores into a 0- to-10 scale, yielding comparable scores on each scale. In order to have a 100-point summary score, each subscale score is multiplied by 2, yielding subscale scores ranging from 1 to 20. A summary UPSA score is calculated by summing these five scores, resulting in total scores ranging from 0 to 100. Scores of 0 represent maximum severity of functional impairment and a score of 100 represents total absence of functional disability.
Functional Outcome measured by the World Health Organization Disability Assessment Schedule (WHODAS 2.0).
The 36-item version of WHODAS 2.0 allows users to generate scores for the six domains of functioning and to calculate an overall functioning score. The scores assigned to each of the items - "none" (1), "mild" (2) "moderate" (3), "se- vere" (4) and "extreme" (5) - are summed. A score of 36 represents total absence of disability and 180 maximum severity of disability.
Functional Outcome measured by the Short Form (36) Health Survey (SF-36).
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Physical Condition measured by the Modified Shuttle Walking Test
Heart rate achieved when walking between 2 cones spaced 10 meters at an increasing rate.
Cardiorespiratory Fitness measured with the Peak Oxygen Uptake (VO2 max)
maximum rate of oxygen consumption measured during incremental exercise (exercise of increasing intensity)
Weight.
Weight in Kg
Height
Height in meters.
Body composition measured with Body Mass Index (BMI)
The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m2, resulting from mass in kilograms and height in metres.
Abdominal Perimeter
Abdominal perimeter measured in centimeters.
Body Composition measured with Total Body Water.
Percentage of Total Body Water measured by Bioimpedance.
Body Composition measured with Body Fat.
Percentage of Body Fat measured by Bioimpedance.
Blood Pressure (systolic and diastolic)
Blood Pressure (systolic and diastolic) measured in millimeters of mercury (mmHg)
Fasting Blood Glucose Levels
Fasting Blood Glucose Levels measured in mg/dl.
Fasting Cholesterol Levels
Fasting Cholesterol Levels measured in mg/dl.
Daily Physical Activity and Sedentary Behavior measured by the International Physical Activity Questionnaire.
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.
Level of Daytime Sleepiness measured by Epworth Sleepiness Scale (ESS)ESS-EPWORTH.
The ESS measures a person's general level of daytime sleepiness, or their average sleep propensity in daily life (ASP). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.
Intensity of Daily Physical Activity measured by the Accelerometer.
Measurement of body movement in terms of accelerations.
Cognition-Processing Speed
WAIS III test: Digit Symbol-Coding. Measured in number of symbols correctly entered in 2 minutes.
Cognition-Attention/Vigilance Stroop Test
Stroop Test: measured in the number of items read or named in 45 seconds for each of the three sheets (word, color, and color-word).
Cognition-Working Memory Digit Span Backward
WAIS IV test: Digit Span Backward subtest. Measured with the number of sequences of numbers recalled in inverse order.
Cognition-Verbal Learning/Memory
Hopkins Verbal Learning Test-Revised (HVLT-R): number of correct words recalled.
Cognition-Reasoning/Problem Solving
Modified Wisconsin Card Sorting Test (M-WCST): score achieved at the M-WCST.
Cognition-Cognitive Reserve
Spanish version of the Word Accentuation Test (TAP-E). Measured with the number of correct attempts.
Cognition-Figural Creativity
Torrance Test of Creative Thinking: Picture Completion subtest. Measured with Fluency, Originality, Elaboration, Resistance to Premature Closure, Abstractness of Titles, and Creative Strengths dimensions obtained from the drawings made in the task.
Cognition-Verbal Creativity
Torrance Test of Creative Thinking: Unusual Uses subtest. Measured with Fluency, Originality, and Flexibility dimensions obtained from the written unusual uses for cardboard boxes and tin cans.
Social Cognition-Social Attribution
Social Attribution Test (SAT). SAT is comprised of a 64 second animation with geometric figures enacting a social drama and 19 multiple-choice questions about the animation. Four possible responses are given to each question. Each correct response is scored with 1 point. Total score ranges from 0 to 19.
Social Cognition-Emotion Recognition
Bell Lysaker Emotion Recognition Task (BLERT). BLERT consists of 21 short video clips in which an actor displays one of seven emotions with three neutral monologues. The examinee is asked to indicate which emotion the actor is portraying. Each correct response is scored with 1 point. The total score is obtained from the sum of each correct emotion recognition, ranging from 0 to 21.
Social Cognition-Theory of Mind
Happe's "Strange Stories Task" Test. Strange Stories Task is comprised of 8 stories concerning double bluff, mistakes, persuasion, and white lies. Each story is scored from 0 to 2. Higher scores indicate a better performance in theory of mind.
Social Functioning measured by the Social Functioning Scale Short-Form (SFS-15)
The SFS-15 is a 15-item scale designed to measure social functioning in patients with schizophrenia. It includes items about isolation, interpersonal communication, independence-execution, independence-competence, and employment-occupation. 13 of the items range from 0 to 3 and the other 2 items range from 1 to 2. Total score is obtained from the sum of the 15 items. Total score range from 1 to 43 points. Higher scores indicate higher level of social functioning.
Self-Efficacy measured by the General Self-Efficacy Scale
General Self-Efficacy Scale is a 10-item scale that measures optimistic self-beliefs to cope with a variety of difficult demands in life. The scores assigned to each of the item - "Not at all true" (1), "Hardly true" (2), "Moderately true" (3), and "Exactly true" (4) - are summed. The final score ranges from 10 to 40, higher scores indicating a higher level of self-efficacy.
Social Anhedonia measured with the Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
The ACIPS is a 17-item scale that consists of 7 anticipatory and 10 consummatory items. The scores assigned to each of the items range from 1 (very false for me) to 6 (very true for me). Total score is obtained from the sum of the 17 items. Higher scores indicate higher ability to experience interpersonal pleasure.
Handedness measured by the Edinburgh Handedness Inventory
A self-report questionnaire assessing the dominance of a person's right or left hand in ten different everyday activities.
Treatment satisfaction measured by the Spanish version of Consumer Reports Effectiveness Scale (CRES-4)
CRES-4 consists of a 4-item scale designed to evaluate patient's satisfaction with the received therapy. Its global score reflects treatment effectiveness as perceived by the patient. 3 components can be obtained: "satisfaction" (based on the first item, which ranges from 0 to 5), "problem resolution" (based on the second item, which ranges from 0 to 5), and "perceived emotional change" (obtained from the subtraction of the third from the fourth item, which range from 0 to 4). The "satisfaction" component is multiplied by 20, the "problem resolution" by 20 and the "perceived emotional change" by 12.5. Final score is obtained from the sum of the three components, ranging from 0 to 300. Higher scores indicate a greater perception of treatment efficacy.

Full Information

First Posted
April 11, 2018
Last Updated
July 26, 2019
Sponsor
Red Salud Mental Araba
Collaborators
University of Deusto, University of the Basque Country (UPV/EHU)
search

1. Study Identification

Unique Protocol Identification Number
NCT03509597
Brief Title
Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia
Acronym
CORTEX-SP
Official Title
A Randomized, Open-Label, Parallel-Group Study to Investigate The Effect of Cognitive Training and Aerobic Exercise on Brain, Functional Outcome and Cognition in Schizophrenia
Study Type
Interventional

2. Study Status

Record Verification Date
July 2019
Overall Recruitment Status
Unknown status
Study Start Date
March 1, 2017 (Actual)
Primary Completion Date
December 31, 2019 (Anticipated)
Study Completion Date
June 1, 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Red Salud Mental Araba
Collaborators
University of Deusto, University of the Basque Country (UPV/EHU)

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the brain correlates of Cognitive Training and Aerobic Exercise in schizophrenia. A third of participants will receive Cognitive Training plus Standard Care for schizophrenia. Another third of participants will receive Aerobic Exercise Training plus Standard Care for schizophrenia. A control group will of participants will receive Standard Care plus Occupational Activities for the same duration and frequency as the experimental groups.
Detailed Description
This study, randomized, open, controlled with schizophrenia-standard-care, is aimed to determine structural and functional brain changes associated to cognitive remediation and physical exercise in schizophrenia. The study participants will be enrolled in the catchment area of the Hospital Psiquiatrico de Alava, in the province of Alava, Basque Region, Northern Spain.147 patients diagnosed with schizophrenia will be randomly assigned to Cognitive Training Group or Aerobic Exercise Group or a Control Group for a five-month period. Both Cognitive Training Group patients and Aerobic Exercise Group patients will participate in training sessions of 60 min/d, 3 d/wk. Patients assigned to Control Group will receive the standard care for schizophrenia in this area plus occupational activities for the same duration and frequency than the two experimental groups. Cognitive Training will be implemented through REHACOP, a cognitive remediation program for Spanish speaking patients with schizophrenia whose efficacy on cognitive performance and negative symptoms has already been demonstrated in patients with schizophrenia. REHACOP is a "paper & pencil" based cognitive remediation program that covers 8 cognitive domains including social cognition. It is based on the principles of Optimization, Restauration & Compensation. Aerobic Exercise Training will consist of an intensive physical exercise program supervised by certified graduates and doctorate students of Physical Activity and Sport Sciences. Sessions will include 10-minute warming-up and 10-minute back exercises and stretches. The main part of the session will consist of aerobic exercise (20-minute indoor bicycle) and muscle-resistance and strength exercises for 20 minutes. The intensity of the sessions will be determined on a case by case basis according to the HR necessary to achieve the intensity ranges (R2-moderate and R3-high). During the sessions, the bicycle's power and pace will be individually adjusted to achieve the selected HR. The assessment batteries, neuroimaging and Serum BDNF levels will be administered and determined at baseline and immediately following the completion of the Cognitive Remediation or Aerobic Exercise interventions. Primary outcomes: Structural and functional brain changes will be assessed by MRI neuroimaging. A Philips Achieva 3.0T MRI system equipped with a modular 32-channel architecture. 3 different types of images will be acquired: a) T1-weighted MRI imaging, b) Diffusion Tensor imaging, c) fMRI imaging at rest and using a cognitive paradigm. Secondary outcomes will be changes in cognitive performance, clinical and functional changes and Serum BDNF changes.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Schizophrenia
Keywords
Cognitive remediation, Aerobic exercise, Physical exercise, Negative symptoms, Functional outcome, Cognition

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized parallel assignment: Cognitive Training, Aerobic Exercise & Treatment as usual.
Masking
InvestigatorOutcomes Assessor
Masking Description
Patients are trained to not comment about the type of treatment they have been assigned to with the investigator who performs the assessments.
Allocation
Randomized
Enrollment
150 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Aerobic Exercise
Arm Type
Experimental
Arm Description
This program consists of an exercise dosage of 180 min/week administered in 3 sessions of 60 minutes. Each session includes 10 minutes of warm-up exercise before the main exercise and 10 minutes of cool-down afterwards.the principal exercise section includes 20 minutes of aerobic exercise and 20 minutes of resistance and strength exercises. The exercise intensity will be regulated according to the heart rate measured by a pulsimeter throughout the exercise. The target intensity level will be individualized according to the heart rate to set the moderate intensity level (HR values between ventilatory thresholds) and high intensity level (HR values from 2nd. ventilatory threshold to the peak threshold).
Arm Title
Cognitive Training
Arm Type
Experimental
Arm Description
The CT group participates in a cognitive remediation program. This program consists of 3 sessions of 60 minutes per week. CT will be administered in groups of 5-8 subjects. The cognitive domains involved in the CT are attention/concentration, memory/learning, language, executive functions, social cognition, social skills, daily living activities and psychoeducation. Cognitive Remediation will be provided by using REHACOP, a cognitive remediation training tool designed and validated for Spanish patients with schizophrenia.
Arm Title
Treatment as usual
Arm Type
Sham Comparator
Arm Description
The TaU Group receives the usual treatment that patients with schizophrenia in Spain enriched with occupational activities administered 3 times a week with a duration of 60 minutes each session.
Intervention Type
Behavioral
Intervention Name(s)
Aerobic Exercise
Intervention Description
Physical exercise training consisting of aerobic exercise and strength/resistance training.
Intervention Type
Behavioral
Intervention Name(s)
Cognitive Training
Intervention Description
Cognitive remediation program using REHACOP rehabilitation program.
Intervention Type
Behavioral
Intervention Name(s)
Treatment as usual
Intervention Description
Standard care for schizophrenia + Leisure and free time activities.
Intervention Type
Behavioral
Intervention Name(s)
Occupational Activities
Intervention Description
Engagement in activities aimed to keep patients actively involved in demanding tasks.
Primary Outcome Measure Information:
Title
Grey Matter Volume Change
Description
Assessment of Grey Matter volume changes (T1-weighted MRI) among the 3 groups using Voxel Based Morphometry (VBM).
Time Frame
5 months
Title
Fractional Anisotropy Change
Description
Assessment of changes in fractional anisotropy of White Matter fibers by Diffusion Tensor MR Imaging and using the Tract-Based Spatial Statistics (TBSS).
Time Frame
5 months
Title
Functional Magnetic Resonance Imaging (fMRI) Change at Rest
Description
Assessment of changes in fMRI at rest with the Coon Functional Connectivity Toolbox.
Time Frame
5 months
Title
Functional Magnetic Resonance Imaging (fMRI) Change during the performance of a cognitive paradigm.
Description
Assessment of changes in fMRI during the performance of a cognitive paradigm with Statistical Parametric Mapping (SPM8).
Time Frame
5 months
Secondary Outcome Measure Information:
Title
Serum BDNF
Description
Assessment of changes in serum BDNF using ELISA immuno-assay techniques. Measured in ng/ml.
Time Frame
5 months.
Title
Clinical Symptoms of Schizophrenia measured by the Positive and Negative Symptoms Scale (PANSS).
Description
Severity of the negative symptoms will be assessed with the total score of the Subscale for Negative Symptoms of the PANSS scale, which comprises 7 items, each one measuring a specific negative symptom. Each item ranges from 1 (absence of the symptom) to 7 (extreme severity of the symptom). Total score of the Negative Subscale of the PANSS ranges from 7 (minimum score) to 49 (maximum severity). Severity of positive symptoms will be assessed with the total score of the Subscale for Positive Symptoms of the PANSS, which comprises 7 items ranging from 1 (absence of the symptom) to 7 (extreme severity of the symptom). Total score of the Positive Subscale ranges from 7 (minimun score) to 49 (maximun severity). General Psychopathology will be assessed with the total score of the General Psychopathology Subscale which comprises 16 items ranging from 1(absence of the symptom) to 7 (extreme severity of the symptom).
Time Frame
5 months.
Title
Negative Symptoms of Schizophrenia measured by the Brief Negative Symptoms Scale (BNSS).
Description
Severity of negative symptoms will be assessed with the total score of the BNSS. Values ranges from 0 (total absence of negative symptoms) to 90 (maximum severity of negative symptoms).
Time Frame
5 months
Title
Negative Symptoms of Schizophrenia measured by the Clinical Assessment Interview for Negative Symptoms Scale (CAINS)
Description
Severity of negative symptoms will be assessed with the total score of the CAINS scale. Values ranges from 0 (total absence of negative symptoms) to 52 (maximum severity of negative symptoms).
Time Frame
5 months
Title
Functional Outcome measured by the UCSD Performance Based Assessment of Functional Skills in Severe Mental Illness (UPSA).
Description
The UPSA includes the following 5 subscales: Financial Skills, Communication, Comprehension/Planning, Transportation, Household Management. Total scores for each subscale are calculated by transforming raw scores into a 0- to-10 scale, yielding comparable scores on each scale. In order to have a 100-point summary score, each subscale score is multiplied by 2, yielding subscale scores ranging from 1 to 20. A summary UPSA score is calculated by summing these five scores, resulting in total scores ranging from 0 to 100. Scores of 0 represent maximum severity of functional impairment and a score of 100 represents total absence of functional disability.
Time Frame
5 months
Title
Functional Outcome measured by the World Health Organization Disability Assessment Schedule (WHODAS 2.0).
Description
The 36-item version of WHODAS 2.0 allows users to generate scores for the six domains of functioning and to calculate an overall functioning score. The scores assigned to each of the items - "none" (1), "mild" (2) "moderate" (3), "se- vere" (4) and "extreme" (5) - are summed. A score of 36 represents total absence of disability and 180 maximum severity of disability.
Time Frame
5 months
Title
Functional Outcome measured by the Short Form (36) Health Survey (SF-36).
Description
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability.
Time Frame
5 months
Title
Physical Condition measured by the Modified Shuttle Walking Test
Description
Heart rate achieved when walking between 2 cones spaced 10 meters at an increasing rate.
Time Frame
5 months
Title
Cardiorespiratory Fitness measured with the Peak Oxygen Uptake (VO2 max)
Description
maximum rate of oxygen consumption measured during incremental exercise (exercise of increasing intensity)
Time Frame
5 months
Title
Weight.
Description
Weight in Kg
Time Frame
5 months
Title
Height
Description
Height in meters.
Time Frame
5 months
Title
Body composition measured with Body Mass Index (BMI)
Description
The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg/m2, resulting from mass in kilograms and height in metres.
Time Frame
5 months.
Title
Abdominal Perimeter
Description
Abdominal perimeter measured in centimeters.
Time Frame
5 months
Title
Body Composition measured with Total Body Water.
Description
Percentage of Total Body Water measured by Bioimpedance.
Time Frame
5 months
Title
Body Composition measured with Body Fat.
Description
Percentage of Body Fat measured by Bioimpedance.
Time Frame
5 months
Title
Blood Pressure (systolic and diastolic)
Description
Blood Pressure (systolic and diastolic) measured in millimeters of mercury (mmHg)
Time Frame
5 months
Title
Fasting Blood Glucose Levels
Description
Fasting Blood Glucose Levels measured in mg/dl.
Time Frame
5 months
Title
Fasting Cholesterol Levels
Description
Fasting Cholesterol Levels measured in mg/dl.
Time Frame
5 months
Title
Daily Physical Activity and Sedentary Behavior measured by the International Physical Activity Questionnaire.
Description
This measure assesses the types of intensity of physical activity and sitting time that people do as part of their daily lives are considered to estimate total physical activity in MET-min/week and time spent sitting.
Time Frame
5 months
Title
Level of Daytime Sleepiness measured by Epworth Sleepiness Scale (ESS)ESS-EPWORTH.
Description
The ESS measures a person's general level of daytime sleepiness, or their average sleep propensity in daily life (ASP). The ESS is a self-administered questionnaire with 8 questions. Respondents are asked to rate, on a 4-point scale (0-3), their usual chances of dozing off or falling asleep while engaged in eight different activities. The higher the ESS score, the higher that person's average sleep propensity in daily life (ASP), or their 'daytime sleepiness'.
Time Frame
5 months
Title
Intensity of Daily Physical Activity measured by the Accelerometer.
Description
Measurement of body movement in terms of accelerations.
Time Frame
5 months
Title
Cognition-Processing Speed
Description
WAIS III test: Digit Symbol-Coding. Measured in number of symbols correctly entered in 2 minutes.
Time Frame
5 months
Title
Cognition-Attention/Vigilance Stroop Test
Description
Stroop Test: measured in the number of items read or named in 45 seconds for each of the three sheets (word, color, and color-word).
Time Frame
5 months
Title
Cognition-Working Memory Digit Span Backward
Description
WAIS IV test: Digit Span Backward subtest. Measured with the number of sequences of numbers recalled in inverse order.
Time Frame
5 months
Title
Cognition-Verbal Learning/Memory
Description
Hopkins Verbal Learning Test-Revised (HVLT-R): number of correct words recalled.
Time Frame
5 months
Title
Cognition-Reasoning/Problem Solving
Description
Modified Wisconsin Card Sorting Test (M-WCST): score achieved at the M-WCST.
Time Frame
5 months
Title
Cognition-Cognitive Reserve
Description
Spanish version of the Word Accentuation Test (TAP-E). Measured with the number of correct attempts.
Time Frame
5 months
Title
Cognition-Figural Creativity
Description
Torrance Test of Creative Thinking: Picture Completion subtest. Measured with Fluency, Originality, Elaboration, Resistance to Premature Closure, Abstractness of Titles, and Creative Strengths dimensions obtained from the drawings made in the task.
Time Frame
5 months
Title
Cognition-Verbal Creativity
Description
Torrance Test of Creative Thinking: Unusual Uses subtest. Measured with Fluency, Originality, and Flexibility dimensions obtained from the written unusual uses for cardboard boxes and tin cans.
Time Frame
5 months
Title
Social Cognition-Social Attribution
Description
Social Attribution Test (SAT). SAT is comprised of a 64 second animation with geometric figures enacting a social drama and 19 multiple-choice questions about the animation. Four possible responses are given to each question. Each correct response is scored with 1 point. Total score ranges from 0 to 19.
Time Frame
5 months
Title
Social Cognition-Emotion Recognition
Description
Bell Lysaker Emotion Recognition Task (BLERT). BLERT consists of 21 short video clips in which an actor displays one of seven emotions with three neutral monologues. The examinee is asked to indicate which emotion the actor is portraying. Each correct response is scored with 1 point. The total score is obtained from the sum of each correct emotion recognition, ranging from 0 to 21.
Time Frame
5 months
Title
Social Cognition-Theory of Mind
Description
Happe's "Strange Stories Task" Test. Strange Stories Task is comprised of 8 stories concerning double bluff, mistakes, persuasion, and white lies. Each story is scored from 0 to 2. Higher scores indicate a better performance in theory of mind.
Time Frame
5 months
Title
Social Functioning measured by the Social Functioning Scale Short-Form (SFS-15)
Description
The SFS-15 is a 15-item scale designed to measure social functioning in patients with schizophrenia. It includes items about isolation, interpersonal communication, independence-execution, independence-competence, and employment-occupation. 13 of the items range from 0 to 3 and the other 2 items range from 1 to 2. Total score is obtained from the sum of the 15 items. Total score range from 1 to 43 points. Higher scores indicate higher level of social functioning.
Time Frame
5 months
Title
Self-Efficacy measured by the General Self-Efficacy Scale
Description
General Self-Efficacy Scale is a 10-item scale that measures optimistic self-beliefs to cope with a variety of difficult demands in life. The scores assigned to each of the item - "Not at all true" (1), "Hardly true" (2), "Moderately true" (3), and "Exactly true" (4) - are summed. The final score ranges from 10 to 40, higher scores indicating a higher level of self-efficacy.
Time Frame
5 months
Title
Social Anhedonia measured with the Anticipatory and Consummatory Interpersonal Pleasure Scale (ACIPS)
Description
The ACIPS is a 17-item scale that consists of 7 anticipatory and 10 consummatory items. The scores assigned to each of the items range from 1 (very false for me) to 6 (very true for me). Total score is obtained from the sum of the 17 items. Higher scores indicate higher ability to experience interpersonal pleasure.
Time Frame
5 months
Title
Handedness measured by the Edinburgh Handedness Inventory
Description
A self-report questionnaire assessing the dominance of a person's right or left hand in ten different everyday activities.
Time Frame
5 months
Title
Treatment satisfaction measured by the Spanish version of Consumer Reports Effectiveness Scale (CRES-4)
Description
CRES-4 consists of a 4-item scale designed to evaluate patient's satisfaction with the received therapy. Its global score reflects treatment effectiveness as perceived by the patient. 3 components can be obtained: "satisfaction" (based on the first item, which ranges from 0 to 5), "problem resolution" (based on the second item, which ranges from 0 to 5), and "perceived emotional change" (obtained from the subtraction of the third from the fourth item, which range from 0 to 4). The "satisfaction" component is multiplied by 20, the "problem resolution" by 20 and the "perceived emotional change" by 12.5. Final score is obtained from the sum of the three components, ranging from 0 to 300. Higher scores indicate a greater perception of treatment efficacy.
Time Frame
5 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of Schizophrenia (DSM-5 F20.9) More than 2 years since the onset of the disease. Stable cognitive impairment. Moderate severity of cognitive impairment in MATRICS scores (T score < 40 in, at least, 1 out of 7 cognitive domains). Exclusion Criteria: Subjects clinically unstable (PANSS positive score > 19). Cognitive impairment due to another medical condition (neurocognitive disorders, brain injury, intellectual disability, etc.)
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Pedro M Sanchez Gomez, MD
Phone
+34 945006555
Ext
6558
Email
gomepe@mac.com
First Name & Middle Initial & Last Name or Official Title & Degree
Edorta J Elizagarate Zabala, MD
Phone
+34 945006555
Email
eduardojose.elizagaratezabala@osakidetza.eus
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Pedro M Sanchez Gomez, MD
Organizational Affiliation
Hospital Psiquiatrico de Alava. Red de Salud Mental de Araba.
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Psiquiatrico de Alava. Red Salud Mental de Araba
City
Vitoria
State/Province
Alava
ZIP/Postal Code
01006
Country
Spain
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Pedro M. S Gomez, MD
Phone
+34 945006555
Ext
6558
Email
gomepe@mac.com
First Name & Middle Initial & Last Name & Degree
Edorta J Elizagarate Zabala, MD
Phone
+34 945 00 6555
Email
eduardojose.elizagaratezabala@osakidetza.eus

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
23686130
Citation
Sanchez P, Pena J, Bengoetxea E, Ojeda N, Elizagarate E, Ezcurra J, Gutierrez M. Improvements in negative symptoms and functional outcome after a new generation cognitive remediation program: a randomized controlled trial. Schizophr Bull. 2014 May;40(3):707-15. doi: 10.1093/schbul/sbt057. Epub 2013 May 18.
Results Reference
result
PubMed Identifier
22403146
Citation
Ojeda N, Pena J, Bengoetxea E, Garcia A, Sanchez P, Elizagarate E, Segarra R, Ezcurra J, Gutierrez-Fraile M, Eguiluz JI. [REHACOP: a cognitive rehabilitation programme in psychosis]. Rev Neurol. 2012 Mar 16;54(6):337-42. Spanish.
Results Reference
result
PubMed Identifier
29525739
Citation
Pena J, Ibarretxe-Bilbao N, Sanchez P, Uriarte JJ, Elizagarate E, Gutierrez M, Ojeda N. Mechanisms of functional improvement through cognitive rehabilitation in schizophrenia. J Psychiatr Res. 2018 Jun;101:21-27. doi: 10.1016/j.jpsychires.2018.03.002. Epub 2018 Mar 6.
Results Reference
result
PubMed Identifier
27868083
Citation
Pena J, Ibarretxe-Bilbao N, Sanchez P, Iriarte MB, Elizagarate E, Garay MA, Gutierrez M, Iribarren A, Ojeda N. Combining social cognitive treatment, cognitive remediation, and functional skills training in schizophrenia: a randomized controlled trial. NPJ Schizophr. 2016 Nov 9;2:16037. doi: 10.1038/npjschz.2016.37. eCollection 2016.
Results Reference
result
PubMed Identifier
22573504
Citation
Ojeda N, Pena J, Bengoetxea E, Garcia A, Sanchez P, Elizagarate E, Segarra R, Ezcurra J, Gutierrez-Fraile M, Eguiluz JI. [Evidence of the effectiveness of cognitive rehabilitation in psychosis and schizophrenia with the REHACOP programme]. Rev Neurol. 2012 May 16;54(10):577-86. Spanish.
Results Reference
result
PubMed Identifier
22349843
Citation
Ojeda N, Pena J, Sanchez P, Bengoetxea E, Elizagarate E, Ezcurra J, Gutierrez Fraile M. Efficiency of cognitive rehabilitation with REHACOP in chronic treatment resistant Hispanic patients. NeuroRehabilitation. 2012;30(1):65-74. doi: 10.3233/NRE-2011-0728.
Results Reference
result
PubMed Identifier
33246589
Citation
Tous-Espelosin M, de Azua SR, Iriarte-Yoller N, MartinezAguirre-Betolaza A, Sanchez PM, Corres P, Arratibel-Imaz I, Sampedro A, Pena J, Maldonado-Martin S. Clinical, physical, physiological, and cardiovascular risk patterns of adults with schizophrenia: CORTEX-SP study: Characterization of adults with schizophrenia. Psychiatry Res. 2021 Jan;295:113580. doi: 10.1016/j.psychres.2020.113580. Epub 2020 Nov 18.
Results Reference
derived

Learn more about this trial

Brain Image Markers Associated With Cognitive Training and Aerobic Exercise in Schizophrenia

We'll reach out to this number within 24 hrs